Therapies in inborn errors of oxidative metabolism

Trends in Endocrinology and Metabolism

Volumn 23, Issue 9, 2012, Pages 488-495

  Schiff, Manuel ^a,b,c   Bénit, Paule ^a,b   Jacobs, Howard T ^d   Vockley, Jerry ^c   Rustin, Pierre ^a,b  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Clinical trials; Idebenone; Mitochondrial therapy; MNGIE

Indexed keywords

ADENOSINE TRIPHOSPHATE; UBIDECARENONE;

AEROBIC METABOLISM; ENVIRONMENTAL FACTOR; EPIGENETICS; EXERCISE; GENE EXPRESSION; GENE FUNCTION; HUMAN; INBORN ERROR OF METABOLISM; NONHUMAN; NUTRITION; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW;

ANIMALS; CLINICAL TRIALS AS TOPIC; DNA, MITOCHONDRIAL; GENETIC THERAPY; HUMANS; METABOLISM, INBORN ERRORS; MITOCHONDRIA; MITOCHONDRIAL DISEASES;

EID: 84865405029     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2012.04.006     Document Type: Review

References (80)

1. Chinnery P.F., et al. Epigenetics, epidemiology and mitochondrial DNA diseases. Int. J. Epidemiol. 2012, 41:177-187.
2. Wallace D.C., et al. Mitochondrial energetics and therapeutics. Annu. Rev. Pathol. 2010, 5:297-348.
3. Benit P., et al. Genetic background influences mitochondrial function: modeling mitochondrial disease for therapeutic development. Trends Mol. Med. 2010, 16:210-217.
4. Hirano M., et al. CoQ(10) deficiencies and MNGIE: two treatable mitochondrial disorders. Biochim. Biophys. Acta. 2012, 1820:625-631.
5. Koopman W.J., et al. Monogenic mitochondrial disorders. N. Engl. J. Med. 2012, 366:1132-1141.
6. Larsson N.G., Clayton D.A. Molecular genetic aspects of human mitochondrial disorders. Annu. Rev. Genet. 1995, 29:151-178.
7. Stewart J.B., et al. Strong purifying selection in transmission of mammalian mitochondrial DNA. PLoS Biol. 2008, 6:e10.
8. Jensen N.M., et al. An update on targeted gene repair in mammalian cells: methods and mechanisms. J. Biomed. Sci. 2011, 18:10.
9. Bonnefoy N., Fox T.D. Genetic transformation of Saccharomyces cerevisiae mitochondria. Methods Cell Biol. 2001, 65:381-396.
10. Rustin P., et al. Targeting allotopic material to the mitochondrial compartment: new tools for better understanding mitochondrial physiology and prospect for therapy. Med. Sci. (Paris) 2007, 23:519-525. (in French).
11. Alverson A.J., et al. Origins and recombination of the bacterial-sized multichromosomal mitochondrial genome of cucumber. Plant Cell 2011, 23:2499-2513.
12. Corral-Debrinski M. mRNA specific subcellular localization represents a crucial step for fine-tuning of gene expression in mammalian cells. Biochim. Biophys. Acta. 2007, 1773:473-475.
13. Perales-Clemente E., et al. Allotopic expression of mitochondrial-encoded genes in mammals: achieved goal, undemonstrated mechanism or impossible task?. Nucleic Acids Res. 2011, 39:225-234.
14. Bacman S.R., et al. Modulating mtDNA heteroplasmy by mitochondria-targeted restriction endonucleases in a 'differential multiple cleavage-site' model. Gene Ther. 2007, 14:1309-1318.
15. Entelis N., et al. A glycolytic enzyme, enolase, is recruited as a cofactor of tRNA targeting toward mitochondria in Saccharomyces cerevisiae. Genes Dev. 2006, 20:1609-1620.
16. Bouaita A., et al. Downregulation of apoptosis-inducing factor in Harlequin mice induces progressive and severe optic atrophy which is durably prevented by AAV2-AIF1 gene therapy. Brain 2012, 135:35-52.
17. Campuzano V., et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996, 271:1423-1427.
18. Sandi C., et al. Prolonged treatment with pimelic O-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model. Neurobiol. Dis. 2011, 42:496-505.
19. Bonnefont J.P., et al. Bezafibrate for an inborn mitochondrial beta-oxidation defect. N. Engl. J. Med. 2009, 360:838-840.
20. Marmolino D., et al. PGC-1alpha down-regulation affects the antioxidant response in Friedreich's ataxia. PLoS ONE 2010, 5:e10025.
21. Viscomi C., et al. In vivo correction of COX deficiency by activation of the AMPK/PGC-1alpha Axis. Cell Metab. 2011, 14:80-90.
22. Wenz T., et al. Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype. Cell Metab. 2008, 8:249-256.
23. Yatsuga S., Suomalainen A. Effect of bezafibrate treatment on late-onset mitochondrial myopathy in mice. Hum. Mol. Genet. 2012, 21:526-535.
24. Djouadi F., Bastin J. Species differences in the effects of bezafibrate as a potential treatment of mitochondrial disorders. Cell Metab. 2011, 14:715-716.
25. Lagouge M., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127:1109-1122.
26. Bastin J., et al. Exposure to resveratrol triggers pharmacological correction of fatty acid utilization in human fatty acid oxidation-deficient fibroblasts. Hum. Mol. Genet. 2011, 20:2048-2057.
27. Schiff M., et al. Mitochondrial response to controlled nutrition in health and disease. Nutr. Rev. 2011, 69:65-75.
28. Hakkaart G.A., et al. Allotopic expression of a mitochondrial alternative oxidase confers cyanide resistance to human cell respiration. EMBO Rep. 2006, 7:341-345.
29. Fernandez-Ayala D.J., et al. Expression of the Ciona intestinalis alternative oxidase (AOX) in Drosophila complements defects in mitochondrial oxidative phosphorylation. Cell Metab. 2009, 9:449-460.
30. Dassa E.P., et al. Expression of the alternative oxidase complements cytochrome c oxidase deficiency in human cells. EMBO Mol. Med. 2009, 1:30-36.
31. Yagi T., et al. Possibility of transkingdom gene therapy for complex I diseases. Biochim. Biophys. Acta. 2006, 1757:708-714.
32. Mizuno M., et al. Antenatal glucocorticoid therapy accelerates ATP production with creatine kinase increase in the growth-enhanced fetal rat heart. Circ. J. 2010, 74:171-180.
33. Dimauro S., Rustin P. A critical approach to the therapy of mitochondrial respiratory chain and oxidative phosphorylation diseases. Biochim. Biophys. Acta. 2008, 1792:1159-1167.
34. Salahudeen A.K., et al. Hydrogen peroxide-induced renal injury. A protective role for pyruvate in vitro and in vivo. J. Clin. Invest. 1991, 88:1886-1893.
35. Bayot A., et al. Friedreich's ataxia: the vicious circle hypothesis revisited. BMC Med. 2011, 9:112.
36. Rustin P., et al. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet 1999, 354:477-479.
37. 31P-MRS study. J. Neurol. Sci. 1997, 148:25-31.
38. Geromel V., et al. Coenzyme Q(10) and idebenone in the therapy of respiratory chain diseases: rationale and comparative benefits. Mol. Genet. Metab. 2002, 77:21-30.
39. Meier T., et al. Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study. J. Neurol. 2012, 259:284-291.
40. Hausse A.O., et al. Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart 2002, 87:346-349.
41. Klopstock T., et al. A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy. Brain 2011, 134:2677-2686.
42. Rotig A., et al. Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet 2000, 356:391-395.
43. Quinzii C.M., Hirano M. Primary and secondary CoQ(10) deficiencies in humans. Biofactors 2011, 37:361-365.
44. Selak M.A., et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005, 7:77-85.
45. Briere J.J., et al. Mitochondrial succinate is instrumental for HIF1alpha nuclear translocation in SDHA-mutant fibroblasts under normoxic conditions. Hum. Mol. Genet. 2005, 14:3263-3269.
46. Tomlinson I.P., et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat. Genet. 2002, 30:406-410.
47. O'Flaherty L., et al. Dysregulation of hypoxia pathways in fumarate hydratase-deficient cells is independent of defective mitochondrial metabolism. Hum. Mol. Genet. 2011, 19:3844-3851.
48. Panetta J., et al. Effect of high-dose vitamins, coenzyme Q and high-fat diet in paediatric patients with mitochondrial diseases. J. Inherit. Metab. Dis. 2004, 27:487-498.
49. de Meer K., et al. Increasing fat in the diet does not improve muscle performance in patients with mitochondrial myopathy due to complex I deficiency. J. Inherit. Metab. Dis. 2005, 28:95-98.
50. Roef M.J., et al. Triacylglycerol infusion does not improve hyperlactemia in resting patients with mitochondrial myopathy due to complex I deficiency. Am. J. Clin. Nutr. 2002, 75:228-236.
51. Roef M.J., et al. Triacylglycerol infusion improves exercise endurance in patients with mitochondrial myopathy due to complex I deficiency. Am. J. Clin. Nutr. 2002, 75:237-244.
52. Kliewer S.A., et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:4318-4323.
53. Hancock C.R., et al. High-fat diets cause insulin resistance despite an increase in muscle mitochondria. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:7815-7820.
54. Kang H.C., et al. Safe and effective use of the ketogenic diet in children with epilepsy and mitochondrial respiratory chain complex defects. Epilepsia 2007, 48:82-88.
55. Bough K.J., et al. Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet. Ann. Neurol. 2006, 60:223-235.
56. Masino S.A., Geiger J.D. Are purines mediators of the anticonvulsant/neuroprotective effects of ketogenic diets?. Trends Neurosci. 2008, 31:273-278.
57. Maalouf M., et al. Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation. Neuroscience 2007, 145:256-264.
58. Santra S., et al. Ketogenic treatment reduces deleted mitochondrial DNAs in cultured human cells. Ann. Neurol. 2004, 56:662-669.
59. Ahola-Erkkila S., et al. Ketogenic diet slows down mitochondrial myopathy progression in mice. Hum. Mol. Genet. 2010, 19:1974-1984.
60. Schiff M., et al. Mouse studies to shape clinical trials for mitochondrial diseases: high fat diet in Harlequin mice. PLoS ONE 2011, 6:e28823.
61. Benit P., et al. The variability of the harlequin mouse phenotype resembles that of human mitochondrial-complex I-deficiency syndromes. PLoS ONE 2008, 3:e3208.
62. Roe C.R., et al. Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J. Clin. Invest. 2002, 110:259-269.
63. Watmough N.J., et al. Impaired mitochondrial beta-oxidation in a patient with an abnormality of the respiratory chain. Studies in skeletal muscle mitochondria. J. Clin. Invest. 1990, 85:177-184.
64. Burgess S.C., et al. Diminished hepatic gluconeogenesis via defects in tricarboxylic acid cycle flux in peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha)-deficient mice. J. Biol. Chem. 2006, 281:19000-19008.
65. Zeviani M. Train, train, train! No pain, just gain. Brain 2008, 131:2809-2811.
66. Jeppesen T.D., et al. Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy. Brain 2006, 129:3402-3412.
67. Shoubridge E.A., et al. Complete restoration of a wild-type mtDNA genotype in regenerating muscle fibres in a patient with a tRNA point mutation and mitochondrial encephalomyopathy. Hum. Mol. Genet. 1997, 6:2239-2242.
68. Murphy J.L., et al. Resistance training in patients with single, large-scale deletions of mitochondrial DNA. Brain 2008, 131:2832-2840.
69. Wenz T., et al. Endurance exercise is protective for mice with mitochondrial myopathy. J. Appl. Physiol. 2009, 106:1712-1719.
70. Steiner J.L., et al. Exercise training increases mitochondrial biogenesis in the brain. J. Appl. Physiol. 2011, 111:1066-1071.
71. Safdar A., et al. Endurance exercise rescues progeroid aging and induces systemic mitochondrial rejuvenation in mtDNA mutator mice. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:4135-4140.
72. Apabhai S., et al. Habitual physical activity in mitochondrial disease. PLoS ONE 2011, 6:e22294.
73. Bonnet D., et al. Heart transplantation in children with mitochondrial cardiomyopathy. Heart 2001, 86:570-573.
74. Sokal E.M., et al. Liver transplantation in mitochondrial respiratory chain disorders. Eur. J. Pediatr. 1999, 158(Suppl. 2):S81-S84.
75. Dimmock D.P., et al. Abnormal neurological features predict poor survival and should preclude liver transplantation in patients with deoxyguanosine kinase deficiency. Liver Transpl. 2008, 14:1480-1485.
76. Garone C., et al. Clinical and genetic spectrum of mitochondrial neurogastrointestinal encephalomyopathy. Brain 2011, 134:3326-3332.
77. Yavuz H., et al. Treatment of mitochondrial neurogastrointestinal encephalomyopathy with dialysis. Arch. Neurol. 2007, 64:435-438.
78. Lara M.C., et al. Infusion of platelets transiently reduces nucleoside overload in MNGIE. Neurology 2006, 67:1461-1463.
79. Hirano M., et al. Allogeneic stem cell transplantation corrects biochemical derangements in MNGIE. Neurology 2006, 67:1458-1460.
80. Weber-Lotfi F., et al. Developing a genetic approach to investigate the mechanism of mitochondrial competence for DNA import. Biochim. Biophys. Acta. 2009, 1787:320-327.